616 related articles for article (PubMed ID: 19221167)
1. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
Scagliotti G; Hanna N; Fossella F; Sugarman K; Blatter J; Peterson P; Simms L; Shepherd FA
Oncologist; 2009 Mar; 14(3):253-63. PubMed ID: 19221167
[TBL] [Abstract][Full Text] [Related]
2. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
Scagliotti G; Brodowicz T; Shepherd FA; Zielinski C; Vansteenkiste J; Manegold C; Simms L; Fossella F; Sugarman K; Belani CP
J Thorac Oncol; 2011 Jan; 6(1):64-70. PubMed ID: 21119545
[TBL] [Abstract][Full Text] [Related]
3. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence.
Standfield L; Weston AR; Barraclough H; Van Kooten M; Pavlakis N
Respirology; 2011 Nov; 16(8):1210-20. PubMed ID: 21801275
[TBL] [Abstract][Full Text] [Related]
4. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Scagliotti GV; Parikh P; von Pawel J; Biesma B; Vansteenkiste J; Manegold C; Serwatowski P; Gatzemeier U; Digumarti R; Zukin M; Lee JS; Mellemgaard A; Park K; Patil S; Rolski J; Goksel T; de Marinis F; Simms L; Sugarman KP; Gandara D
J Clin Oncol; 2008 Jul; 26(21):3543-51. PubMed ID: 18506025
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.
Wu YL; Lu S; Cheng Y; Zhou C; Wang M; Qin S; Lu Y; Zhang Y; Zhu Y; Song X; Wang X; Barraclough H; Zhang X; Chi H; Orlando M
Lung Cancer; 2014 Sep; 85(3):401-7. PubMed ID: 25082564
[TBL] [Abstract][Full Text] [Related]
6. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.
Treat J; Scagliotti GV; Peng G; Monberg MJ; Obasaju CK; Socinski MA
Lung Cancer; 2012 May; 76(2):222-7. PubMed ID: 22115704
[TBL] [Abstract][Full Text] [Related]
7. Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer.
Cohen MH; Justice R; Pazdur R
Oncologist; 2009 Sep; 14(9):930-5. PubMed ID: 19737998
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
Syrigos KN; Vansteenkiste J; Parikh P; von Pawel J; Manegold C; Martins RG; Simms L; Sugarman KP; Visseren-Grul C; Scagliotti GV
Ann Oncol; 2010 Mar; 21(3):556-561. PubMed ID: 19828561
[TBL] [Abstract][Full Text] [Related]
9. Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer.
Novello S; Pimentel FL; Douillard JY; O'Brien M; von Pawel J; Eckardt J; Liepa AM; Simms L; Visseren-Grul C; Paz-Ares L
J Thorac Oncol; 2010 Oct; 5(10):1602-8. PubMed ID: 20808252
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
Yang CH; Simms L; Park K; Lee JS; Scagliotti G; Orlando M
J Thorac Oncol; 2010 May; 5(5):688-95. PubMed ID: 20150825
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
[TBL] [Abstract][Full Text] [Related]
13. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.
Ortuzar W; Hanna N; Pennella E; Peng G; Langer C; Monberg M; Scagliotti G
Clin Lung Cancer; 2012 Jan; 13(1):24-30. PubMed ID: 21831719
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
Gridelli C; Rossi A; Di Maio M; Leo S; Filipazzi V; Favaretto AG; Burgio MA; Cinieri S; Bianco R; Ciardiello F; Cavanna L; Bordonaro R; Costanzo R; Sandomenico C; Gallo C; Perrone F; Morabito A
Clin Lung Cancer; 2014 Mar; 15(2):166-70. PubMed ID: 24418693
[TBL] [Abstract][Full Text] [Related]
16. Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer.
Pereira JR; Cheng R; Orlando M; Kim JH; Barraclough H
Drugs R D; 2013 Dec; 13(4):289-96. PubMed ID: 24277116
[TBL] [Abstract][Full Text] [Related]
17. [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
Huang Y; Liu Y; Zhou J; Xu N; Li B; Wu G; Fang J; Li K; Liu X; Liu W; Lu Y; Wang M; Liu W; Liang H; Zhang Y; Huang C; Wang S; Wang Y; Yu S; Chang J; Wang Z; Hu Z; Zhang L
Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):576-82. PubMed ID: 23075681
[TBL] [Abstract][Full Text] [Related]
18. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia.
Chang JW; Thongprasert S; Wright E; Tsang K; Kim HT; Ahn MJ; Kim JH; Kang JH; Kim SW; Walzer S
Asia Pac J Clin Oncol; 2011 Jun; 7 Suppl 2():13-21. PubMed ID: 21585704
[TBL] [Abstract][Full Text] [Related]
19. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.
Zinner RG; Novello S; Peng G; Herbst R; Obasaju C; Scagliotti G
Clin Lung Cancer; 2010 Mar; 11(2):126-31. PubMed ID: 20199979
[TBL] [Abstract][Full Text] [Related]
20. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.
Scagliotti GV; Park K; Patil S; Rolski J; Goksel T; Martins R; Gans SJ; Visseren-Grul C; Peterson P
Eur J Cancer; 2009 Sep; 45(13):2298-303. PubMed ID: 19473833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]